Empty Capsules Market will Hit Big Revenues in Future | COVID-19 Unlock Opportunities

 

Capsules are the second most common form of dosage for the oral administration of drugs after tablets. These are largely used in the nutraceutical and pharmaceutical sectors. Reduction in the timelines of drug development under standard conditions has been the key factor driving the production of drugs delivered in the form of capsules among pharmaceutical and nutraceutical manufacturers. In addition, this strategy enables pharmaceutical manufacturers to reduce the time required to introduce the drug in the market. The other advantage includes protection of a drug substance from various external factors, such as natural or artificial light during production, storage, administration, and use. Furthermore, capsules act as an efficient shield, which prevents the enclosed drugs from decomposition.

The global empty capsules market was valued at $1,841.5 million in 2017 and is projected to reach $3,707.5 million by 2025 growing at a CAGR of 9.1% from 2018 to 2025. Among raw materials, the pig meat segment accounted for three-sevenths share of the total market in 2017.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/985

Based on the product, the global empty capsules market is classified into gelatin capsules and non-gelatin capsules. Gelatin capsules are further bifurcated into hard gelatin capsules (HGCs) and soft gelatin capsules (SGCs). The gelatin segment dominated the global market in 2017 and is expected to maintain this trend throughout the forecast period. Gelatin has been the standard choice of raw material for the development of hard shell capsules that can efficiently hold active pharmaceutical ingredients (APIs). Whereas, the non-gelatin capsules segment are expected to grow at the fastest pace from 2018 to 2025. An increase in demand for hydroxypropyl methylcellulose (HPMC) capsules is the major contributor to the robust CAGR of the non-gelatin capsules segment in the global market. Furthermore, a major shift in consumer behavior has been observed toward the use of vegetarian capsules in the recent years.

Based on therapeutic application, the market is divided into antibiotic & antibacterial drugs, vitamin & dietary supplements, antacids & anti-flatulent preparations, cardiac therapy drugs, and other applications. The antibiotic & antibacterial drugs segment dominated the global market in 2017 and is anticipated to continue this dominance throughout the forecast period. However, the vitamin & dietary supplements segment is expected to grow at the fastest pace throughout the forecast period. Consumption of antibiotics has considerably increased in the recent years. Increasing consumption of antibiotics, either prescription or over-the-counter, has resulted in incessant use of antibiotics for the treatment of ailments across the globe.

The Asia-Pacific region is expected to witness the highest growth rate throughout the forecast period, owing to its high population base, increase in disposable incomes, improvement in patient awareness toward chronic disorders, and adoption of a healthy lifestyle. In addition, countries, such as India and China, serve as major contributors to the growth of the Asia-Pacific empty capsules market, owing to the continuously evolving pharmaceutical industry in these countries.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/985

The Major Key Players Are:

ACG Worldwide, Bright Pharma Caps Inc., CapsCanada Corporation, Lonza Group Ltd. (Capsugel), Medi-Caps Ltd., Mitsubishi Chemical Holdings Corporation (Qualicaps, Inc.), Roxlor LLC, Snail Pharma Industry Co. Ltd, Suheung Co., Ltd, and Sunil Healthcare Ltd.

The other prominent players Are:

Patheon Ltd., Nectar Lifesciences Ltd., JC Biological Technologies, Natural Capsules Ltd., Zhejiang Huili Capsules Co., Ltd., Healthcaps India Limited, HTC Group Limited, and Nanjing Saturn Pharmaceutical Technology Co., Ltd.

Blood Pressure Monitoring Devices Market Top Companies Analysis To Grow Your Business in 2022

Blood pressure is considered as one of the main risk factors for chronic heart disease. Advanced blood pressure monitoringdevices are used for regular remote monitoring and transmission of the blood pressure data to the physicians. Factors such as increase in geriatric population, rise in inclination towards home monitoring, and upsurge in incidence rate of chronic diseases, such as cardiovascular disorders and obesity, are expected to drive the market. Moreover, innovations in blood pressure monitoring devices, (such as introduction of digital blood pressure monitors) and rise in awareness among patients regarding advanced devices are expected to fuel the market growth. However, lack of awareness about these devices in low- and middle-income economies hampers the market growth.

The global blood pressure monitoring devices market was valued at $1,981 million in 2015, and is estimated to reach $2,926 million by 2022, registering a CAGR of 5.7% from 2016 to 2022. Digital blood pressure monitoring devices segment held around two-fifths share of the total market in 2015.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2166

Digital blood pressure monitoring devices segment is anticipated to dominate the global blood pressure monitoring devices market owing to the increase in the global incidence of hypertension. However, ambulatory blood pressure monitors segment is projected to be the fastest growing segment, as a result of increase in the outpatient cases and reimbursement support from the government.

Digital BP monitors at hospitals & clinics segment is expected to dominate the global blood pressure monitoring devices market, as these devices facilitate easy and early detection of a patients deteriorating health condition, thereby, enabling speedy intervention and diagnosis of diseases. However, the ambulatory BP monitoring devices at ambulatory surgical centers (ASCs) market is projected to be the fastest growing segment, owing to increase in the number of outpatient cases.

Inquire before buying @  https://www.alliedmarketresearch.com/purchase-enquiry/2166

North America was the highest revenue contributor to the global revenue in 2015, accounting for about two-fifths share, and is expected to maintain this trend. This is attributed to the increase in prevalence of hypertension, growth in awareness among patients about cost-effective blood pressure monitoring devices, and availability of advanced healthcare facilities in North American countries. However, Asia-Pacific is expected to grow at the highest rate, owing to its high population base, incomes, and improvement in patient awareness about advanced blood pressure monitoring devices.

The Major Key Players Are:

·        A&D Company, Limited

·        Contec Medical Systems Co., Ltd.

·        General Electric Company

·        Halma plc

·        Hill-Rom Holdings, Inc.

·        Koninklijke Philips N.V.

·        Masimo Corporation

·        Nihon Kohden Corporation

·        Omron Corporation

·        Smiths Group Plc.

Diabetic Retinopathy Market Size Prognosticated to Perceive a Thriving Growth by 2022

Diabetic retinopathy (DR) is a medical condition of the eye prevalent in diabetic individuals. It is mainly caused due to damage of the blood vessels of the retina. Without timely treatment, the disease leads to bleeding in the eyes, cloudy vision, and may even destroy the retina. DR is amongst the common cause of loss of vision in the diabetic population. From 1990 to 2010, DR holds the fifth position among the most common causes of preventable blindness and severe visual impairment.

The diabetic retinopathy market was valued at $966 million in 2015, and is projected to reach $2,490 million by 2022, growing at a CAGR of 14.4% from 2016 to 2022. The proliferative diabetic retinopathy segment accounted for more than half of the total market in 2015.

Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/2010

The market is expected to witness significant growth during the forecast period due to factors such as increase in prevalence of diabetes, growth in geriatric population, rise in incidence of blindness due to diabetes, and augment in focus on awareness, which facilitates early diagnosis to control the diseases. Although these factors garner the growth of the market, dearth of skilled ophthalmologists and extended approval time for drugs can pose as a major obstacle for the growth of the diabetic retinopathy market. On the other hand, emergence of combined therapies for treatment of diabetic macular edema, and the emerging markets of the Asia-Pacific and LAMEA regions are anticipated to provide several opportunities for the market growth.

Proliferative diabetic retinopathy segment accounted for a major market share (more than half) in 2015 as the disease is one of the leading causes of blindness in diabetic patients. Moreover, nearly 20% of the people suffering from diabetic retinopathy (any type) have proliferative diabetic retinopathy.

North America accounted for majority of the share (nearly two-fifths) in the market in 2015, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of diabetes along with the rise in geriatric population, increased patient awareness about diabetic retinopathy, and favorable reimbursement framework for retinopathy procedures. In addition, presence of highly sophisticated healthcare infrastructure is anticipated to provide new growth opportunities for the key players in this market.

Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/2010

The major companies profiled Are:

Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals., Bayer AG, F. Hoffmann-La Roche, Novartis International AG, Pfizer, Regeneron Pharmaceuticals Inc., and Valeant Pharmaceutical.

The Other key players Are:

Boehringer Ingelheim GmbH, KOWA Company, Ltd., BCN Peptides S.A., and ThromboGenics NV.